Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Buzzing Stocks Today, Stocks that will see action today: July 18, 2024 - IREDA, Paytm, ONGC, SpiceJet, Bajaj Electricals, Exide Industries, Nazara Tech, Glenmark Pharma, HOEC, TVS Motor, UltraTech, Adani Group, KEC Internatrional, Triveni Egg, Techno Electric, Bajaj Finance, Zee

Stock that will see action today: 18 July 2024

The approval by the US Food & Drug Administration (USFDA) is for Topiramate capsules of strengths 15 mg and 25 mg, Glenmark Pharmaceuticals said in a statement

Glenmark Pharma receives USFDA approval for seizure treatment drug

New Delhi-based Glenmark’s USFDA-approved 15 mg and 25 mg Topiramate capsules, equivalent to Janssen’s Topamax, will be marketed by Glenmark Pharmaceuticals Inc., USA. Topamax had recorded annual sales worth USD 21.9 million per IQVIATM (till May 2024). Glenmark’s US portfolio has 198 products, 50 ANDAs pending, and seeks growth through external development partnerships.

USFDA approves Glenmark Pharma’s seizure treatment drug

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) for Topiramate Capsules USP, 15 mg and 25 mg. Glenmark’s Topiramate Capsules USP, 15 mg and 25 mg has been determined by the FDA to be bioequivalent and therapeutically equivalent1 to Topa…

Corporate

Glenmark receives USFDA approval for Topiramate Capsules

Glenmark Pharmaceuticals said that it has received final approval by US Food & Drug Administration (USFDA) for Topiramate capsules.

Glenmark Pharma gets USFDA approval for seizures drug

Glenmark Life Sciences shares drop 4% as Glenmark Pharmaceuticals exits stake, focusing on CDMO and API growth.

Glenmark Life Sciences dips on Glenmark Pharma’s plan to exit

Shares of Glenmark Pharmaceuticals slipped 1.60 per cent at Rs 1357.30 per share on the Bombay Stock Exchange (BSE) in Thursday’s early morning trade

Glenmark Life, Pharma in focus: Shares fall up to 4% amid stake sale buzz

Glenmark Pharma’s stock rose 1% in early trade to Rs 1,393 apiece on the NSE.

Glenmark Pharma Hits All-Time High On Plan To Exit Glenmark Life

Buzzing Stocks Today, Stocks that will see action today: July 11, 2024 - SBI, UltraTech, Zydus Life, Indo Wind, Sona BLW, Glenmark Pharma, Glenmark Life, IdeaForge, PowerGrid, Oriana Power

Stock that will see action today: 11 July 2024

Stocks to watch, July 11: Global rating agency Moody’s has revised its outlook on Indian private sector lender Yes Bank from “stable” to “positive”

Stocks to watch, July 11: YES Bank, Glenmark Pharma, Nykaa, SBI, Tata Elxsi

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).